Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Rubraca

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
In the current study we investigated the inhibitory effect of rucaparib (Rubraca®) on human ovarian cancer SKOV3 and A2780 cells… Expand
Is this relevant?
2019
2019
In the present study, the interaction between new drug Rubraca and CNT(4,4-8) nanotube by Density Functional Theory (DFT… Expand
Is this relevant?
2019
2019
Poly(ADP-ribose) polymerase-1 (PARP-1) is an enzyme involved in signaling and repair of DNA single strand breaks. PARP-1 employs… Expand
Is this relevant?
2018
2018
  • 2018
  • Corpus ID: 53518531
BOULDER, Colo.-(BUSINESS WIRE) -June 4, 2018-Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the submission of a regulatory… Expand
Is this relevant?
2017
2017
Ovarian cancer is the seventh most common cancer worldwide for females and the most lethal of all gynecological malignancies. The… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2017
2017
Ovarian cancer is the seventh most common cancer worldwide for females and the most lethal of all gynecological malignancies. The… Expand
Is this relevant?
2017
2017
  • 2017
  • Corpus ID: 20909108
NEW DRUG APPROVALS Rubraca for Ovarian Cancer The FDA has granted accelerated approval to rucaparib (Rubraca, Clovis Oncology) to… Expand
Is this relevant?
2017
2017
Epithelial carcinoma of the ovary is one of the most common gynecologic malignancies.1 The National Cancer Institute estimates… Expand
Is this relevant?
2016
2016
The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA… Expand
Is this relevant?